Neutrophil count increased adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,098 adverse event reports that record the MedDRA preferred term Neutrophil count increased. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 376 reports in the 12 months to June 2026 and 520 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,134 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 376 (under 0.1%) record this term. Reports for male patients were 49.1% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 142 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Neutrophil count increased name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	25
Acetaminophen		80
Actemra	Interleukin-6 receptor antagonist	93
Acyclovir	Herpes simplex virus nucleoside analog DNA polymerase inhibitor	32
Adalimumab	Tumor necrosis factor blocker	43
Afinitor	Kinase inhibitor	28
Albuterol	beta2-Adrenergic agonist	31
Albuterol sulfate	beta2-Adrenergic agonist	54
Alemtuzumab	CD52-directed cytolytic antibody	123
Amisulpride	Dopamine-2 receptor antagonist	57
Amlodipine	Calcium channel blocker	37
Ampyra	Potassium channel blocker	44
Aripiprazole	Atypical antipsychotic	122
Aspirin	Nonsteroidal anti-inflammatory drug	64
Atorvastatin		46
Avastin	Vascular endothelial growth factor inhibitor	62
Azathioprine	Purine antimetabolite	67
Basiliximab	Interleukin-2 receptor blocking antibody	81
Benadryl	Histamine-1 receptor antagonist	49
Bevacizumab	Vascular endothelial growth factor inhibitor	44
Candesartan	Angiotensin 2 receptor blocker	42
Capecitabine	Nucleoside metabolic inhibitor	37
Carboplatin	Platinum-based drug	115
Cetirizine	Histamine-1 receptor antagonist	26
Cetirizine hydrochloride	Histamine-1 receptor antagonist	43
Chlorpromazine	Phenothiazine	69
Ciclosporin		35
Cisplatin	Platinum-based drug	89
Citalopram	Serotonin reuptake inhibitor	28
Clozapine	Atypical antipsychotic	1,134
Clozaril	Atypical antipsychotic	3,062
Cosentyx	Interleukin-17A antagonist	49
Cyclobenzaprine	Muscle relaxant	27
Cyclophosphamide	Alkylating drug	171
Cymbalta		61
Cytarabine	Nucleoside metabolic inhibitor	42
Dexamethasone	Corticosteroid	87
Diazepam	Benzodiazepine	34
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	28
Diphenhydramine hydrochloride	Histamine-1 receptor antagonist	46
Docetaxel	Microtubule inhibitor	105
Doxorubicin	Anthracycline topoisomerase inhibitor	85
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	35
Enbrel	Tumor necrosis factor blocker	145
Esomeprazole	Proton pump inhibitor	35
Esomeprazole magnesium	Proton pump inhibitor	31
Esomeprazole Magnesium Naproxen		35
Etoposide	Topoisomerase inhibitor	48
Exemestane	Aromatase inhibitor	27
Filgrastim	Leukocyte growth factor	43
Fluorouracil	Nucleoside metabolic inhibitor	48
Fulvestrant	Estrogen receptor antagonist	25
Furosemide	Loop diuretic	43
Gemcitabine	Nucleoside metabolic inhibitor	40
Gilenya	Sphingosine 1-phosphate receptor modulator	191
Haloperidol	Typical antipsychotic	99
Herceptin	HER2/neu receptor antagonist	25
Humira		164
Ibrance	Kinase inhibitor	30
Ibuprofen	Nonsteroidal anti-inflammatory drug	60
Imbruvica	Kinase inhibitor	32
Imuran	Purine antimetabolite	40
Inflectra	Tumor necrosis factor blocker	52
Infliximab	Tumor necrosis factor blocker	67
Jakafi	Janus kinase inhibitor	50
Jakavi		53
Keytruda	Programmed death Receptor-1 blocking antibody	41
Kisqali	Kinase inhibitor	26
Lapenax		51
Leflunomide	Antirheumatic agent	36
Lemtrada	CD52-directed cytolytic antibody	36
Leponex		53
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	26
Lithium	Mood stabilizer	85
Lorazepam	Benzodiazepine	97
Lyrica		43
Metformin	Biguanide	61
Methotrexate	Folate analog metabolic inhibitor	129
Methotrexate sodium	Folate analog metabolic inhibitor	32
Methylprednisolone	Corticosteroid	120
Methylprednisolone sodium succinate	Corticosteroid	58
Metoprolol	beta-Adrenergic blocker	25
Mirtazapine		41
Mycophenolate mofetil	Antimetabolite immunosuppressant	44
Myfortic	Antimetabolite immunosuppressant	92
Naprosyn		28
Neulasta	Leukocyte growth factor	99
Neupogen	Leukocyte growth factor	26
Obinutuzumab	CD20-directed cytolytic antibody	25
Ocrevus	CD20-directed cytolytic antibody	42
Olanzapine	Atypical antipsychotic	211
Omalizumab	Anti-IgE	34
Omeprazole	Proton pump inhibitor	78
Orencia	Selective T cell costimulation modulator	38
Oxaliplatin	Platinum-based drug	62
Paclitaxel	Microtubule inhibitor	136
Pantoprazole	Proton pump inhibitor	44
Paracetamol		44
Perjeta	HER2/neu receptor antagonist	28
Pertuzumab	HER2/neu receptor antagonist	68
Prednisolone	Corticosteroid	90
Prednisone	Corticosteroid	375
Quetiapine	Atypical antipsychotic	39
Ramipril	Angiotensin converting enzyme inhibitor	65
Remicade	Tumor necrosis factor blocker	48
Revlimid	Thalidomide analog	39
Rinvoq	Janus kinase inhibitor	31
Risperdal	Atypical antipsychotic	73
Risperidone	Atypical antipsychotic	83
Rituxan	CD20-directed cytolytic antibody	61
Rituximab	CD20-directed cytolytic antibody	307
Rosuvastatin	HMG-CoA reductase inhibitor	28
Ruxolitinib	Janus kinase inhibitor	36
Salbutamol		33
Sertraline	Serotonin reuptake inhibitor	49
Sildenafil citrate	Phosphodiesterase 5 inhibitor	44
Simvastatin	HMG-CoA reductase inhibitor	56
Soliris	Complement inhibitor	39
Stelara	Interleukin-12 antagonist	34
Sulfasalazine	Aminosalicylate	41
Symbicort	Corticosteroid	49
Tacrolimus	Calcineurin inhibitor immunosuppressant	97
Tamoxifen		36
Tasigna	Kinase inhibitor	34
Taxol		33
Taxotere		28
Tazobactam		46
Trastuzumab	HER2/neu receptor antagonist	111
Tylenol	Expectorant	49
Valproic acid	Anti-epileptic agent	37
Valsartan	Angiotensin 2 receptor blocker	51
Velcade	Proteasome inhibitor	26
Vincristine		98
Vincristine sulfate	Vinca alkaloid	25
Xeljanz	Janus kinase inhibitor	51
Xgeva	RANK ligand inhibitor	29
Xolair	Anti-IgE	68
Zaponex		192
Zometa		39
Zopiclone		36
Zuclopenthixol		59
Zyprexa	Atypical antipsychotic	42

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Neutrophil count increased name, in order of name
Class	Reports with this term
Alkylating drug	211
Aminosalicylate	57
Angiotensin 2 receptor blocker	144
Angiotensin converting enzyme inhibitor	101
Anthracycline topoisomerase inhibitor	133
Anti-epileptic agent	136
Anti-IgE	102
Antimetabolite immunosuppressant	145
Antirheumatic agent	55
Aromatase inhibitor	83
Atypical antipsychotic	4,811
Benzodiazepine	185
beta-Adrenergic blocker	75
beta2-Adrenergic agonist	85
Biguanide	91
Calcineurin inhibitor immunosuppressant	137
CD20-directed cytolytic antibody	451
CD52-directed cytolytic antibody	166
Corticosteroid	895
Dopamine-2 receptor antagonist	64
Folate analog metabolic inhibitor	188
HER2/neu receptor antagonist	232
Herpes simplex virus nucleoside analog DNA polymerase inhibitor	54
Histamine-1 receptor antagonist	194
HMG-CoA reductase inhibitor	122
Integrin receptor antagonist	58
Interleukin-17A antagonist	51
Interleukin-2 receptor blocking antibody	85
Interleukin-6 receptor antagonist	109
Janus kinase inhibitor	179
Kinase inhibitor	335
Leukocyte growth factor	179
Microtubule inhibitor	243
Mood stabilizer	132
Nonsteroidal anti-inflammatory drug	219
Nucleoside metabolic inhibitor	212
Opioid agonist	113
Phenothiazine	74
Phosphodiesterase 5 inhibitor	61
Platinum-based drug	266
Programmed death Receptor-1 blocking antibody	102
Proton pump inhibitor	228
Purine antimetabolite	113
RANK ligand inhibitor	51
Serotonin reuptake inhibitor	162
Sphingosine 1-phosphate receptor modulator	200
Topoisomerase inhibitor	54
Tumor necrosis factor blocker	407
Typical antipsychotic	99
Vascular endothelial growth factor inhibitor	108

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Neutrophil count increased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Neutrophil count increased
Age	Reports	Share
Under 2	32	0.3%
2 to 11	126	1.2%
12 to 17	149	1.5%
18 to 44	2,370	23.5%
45 to 64	3,293	32.6%
65 to 74	1,173	11.6%
75 and over	709	7%
Age not given	2,246	22.2%

Sex of the patient in the reports that record Neutrophil count increased
Sex	Reports	Share
Female	4,452	44.1%
Male	4,957	49.1%
Unknown or not given	689	6.8%

Age and sex are as the report gives them. 28.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Neutrophil count increased: adverse event reports that record this term. https://reportedreactions.com/reaction/neutrophil-count-increased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Neutrophil count increased mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page